This study explores the clinical significance of serum autoantibody titers and neurofilament light chain (NfL) levels in patients diagnosed with CASPR2/LGI1 autoimmune encephalitis. Researchers investigated these biomarkers longitudinally to understand their relationship with disease progression and patient outcomes. The findings indicate that NfL levels at the onset of the disease can predict long-term cognitive impairment, suggesting their utility in identifying patients requiring tailored management. While autoantibody titers correlate with disease stage and the occurrence of relapses, they do not appear to have prognostic value for long-term functional or cognitive outcomes. The research highlights the potential for a combined assessment of these biomarkers to enhance patient care and management strategies for this specific form of autoimmune encephalitis.